You are here: Industry Insights > thrombosis

News List

RedHill's COVID-19 Candidate Reduces ARDS-Related Blood Clotting in Preclinical Study americanpharmaceuticalreview
December 16, 2020
RedHill Biopharma announced promising preliminary results from a preclinical study within which opaganib, a novel, orally administered sphingosine kinase 2 (SK2) selective inhibitor, (administered at 250mg/kg,) demonstrating a reduction of thrombosis ...
World Thrombosis Day Campaign Shines Spotlight on the Life-Threatening Connection Between Thrombosis and COVID-19 prnasia
October 14, 2020
On October 13, the World Thrombosis Day global campaign shares an important message to "Open Your Eyes to Thrombosis and COVID-19."
Mylan to acquire Aspen’s thrombosis business for $757m pharmaceutical-technology
September 18, 2020
Mylan has agreed to acquire Aspen Pharmacare’s thrombosis business-related intellectual property and commercialisation rights in Europe for €641.9m ($757m).
Mylan to acquire thrombosis business in Europe from Aspen Pharmacare for EUR 641.9 mn expresspharma
September 17, 2020
Transaction expected to be immediately accretive to Mylan upon closing and is anticipated to be accretive to VIATRIS.
Mylan Pays $763M for Aspen's Thrombosis Business in Europe contractpharma
September 15, 2020
Mylan N.V. has reached an agreement to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited's thrombosis business in Europe for approximately $763 million, subject to customary closing conditions ...
BMS ties with Janssen on Factor XIa inhibitor programme pharmatimes
July 16, 2018
Bristol-Myers Squibb and Johnson & Johnson group Janssen have announced a deal to work together on a Factor XIa (FXIa) inhibitor programme, aiming to reduce the risk of vascular events without increasing the risk of bleeding in patients with thrombotic di